# Taiho Pharmaceutical (Otsuka)

Source: https://onco.cc/companies/taiho/  
OnCo record `taiho` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Japanese oncology company behind futibatinib (Lytgobi) for bile duct cancer and the chemotherapy Lonsurf; acquired the ADC linker company Araris in 2025.

## Summary

Taiho Pharmaceutical, the Tokyo-based oncology arm of Otsuka, is the company behind futibatinib, sold as Lytgobi, for bile duct cancer, and the chemotherapy Lonsurf, and in 2025 it acquired the antibody-drug conjugate linker company Araris Biotech. Futibatinib was approved in 2022 on the FOENIX-CCA2 trial for FGFR2-altered cholangiocarcinoma, Lonsurf, or trifluridine and tipiracil, is used in colorectal and gastric cancer with TAS-102 combinations under study, and OnCo also links Taiho to S-1, the tegafur, gimeracil and oteracil combination used in Asia. The Araris purchase signals a move from small molecules into ADCs. Whether a chemotherapy-rooted company can build a competitive ADC pipeline from an acquired linker platform is the open question. Futibatinib and Araris have their own pages.

## Fields

- Kind: Company
- Last checked: 2026-09-07
- HQ: Tokyo
- Type: pharma
- Website: https://www.taiho.co.jp/en/

## Sources

- Official website: https://www.taiho.co.jp/en/

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Futibatinib](https://onco.cc/drugs/futibatinib/), [Tegafur, gimeracil and oteracil (S-1)](https://onco.cc/drugs/tegafur-gimeracil-oteracil/)
- companies: [Araris Biotech (Taiho)](https://onco.cc/companies/araris/), [Otsuka Pharmaceutical](https://onco.cc/companies/otsuka/)
- trials: [ASCERTAIN-V](https://onco.cc/trials/ascertain-v/), [FOENIX-CCA2](https://onco.cc/trials/foenix-cca2/), [JASPAC 01](https://onco.cc/trials/jaspac-01/), [RECOURSE](https://onco.cc/trials/recourse/), [TAPUR (Targeted Agent and Profiling Utilization Registry)](https://onco.cc/trials/tapur/)
- key papers: [Randomized trial of TAS-102 for refractory metastatic colorectal cancer (RECOURSE)](https://onco.cc/key-papers/paper-mayer-recourse-tas-102-nejm-2015/), [Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT)](https://onco.cc/key-papers/paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023/)

---
JSON: https://onco.cc/api/v1/entities/taiho.json